drugset / Trial / NCT06752798
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as an adjuvant treatment for Head and neck cancer after surgery
Timeline
- Start
- 2024-12-30
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | 240 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |